PT - JOURNAL ARTICLE AU - Izzi-Engbeaya, Chioma AU - Distaso, Walter AU - Amin, Anjali AU - Yang, Wei AU - Idowu, Oluwagbemiga AU - Kenkre, Julia S AU - Shah, Ronak J AU - Woin, Evelina AU - Shi, Christine AU - Alavi, Nael AU - Bedri, Hala AU - Brady, Niamh AU - Blackburn, Sophie AU - Leczycka, Martina AU - Patel, Sanya AU - Sokol, Elizaveta AU - Toke-Bjolgerud, Edward AU - Qayum, Ambreen AU - Abdel-Malek, Mariana AU - Hope, David C D AU - Oliver, Nick S AU - Bravis, Vasiliki AU - Misra, Shivani AU - Tan, Tricia M AU - Hill, Neil AU - Salem, Victoria TI - Severe COVID-19 and Diabetes - A Retrospective Cohort Study from Three London Teaching Hospitals AID - 10.1101/2020.08.07.20160275 DP - 2020 Jan 01 TA - medRxiv PG - 2020.08.07.20160275 4099 - http://medrxiv.org/content/early/2020/08/11/2020.08.07.20160275.short 4100 - http://medrxiv.org/content/early/2020/08/11/2020.08.07.20160275.full AB - Patients with diabetes mellitus admitted to hospital with COVID-19 caused by infection with the novel coronavirus (SARS-CoV-2) have poorer outcomes. However, the drivers for this are not fully elucidated. We performed a retrospective cohort study, including detailed pre-hospital and presenting clinical and biochemical factors of 889 patients diagnosed with COVID-19 in three constituent hospitals of a large London NHS Trust. 62% of patients with severe COVID-19 were of non-White ethnic backgrounds and the prevalence of diabetes was 38%. 323 (36%) patients met the primary outcome of death or admission to the intensive care unit (ICU) within 30 days of diagnosis. Male gender, advancing age and the Clinical Frailty Scale, an established measure of multimorbidity, independently predicted poor outcomes on multivariate analysis. Diabetes did not confer an independent risk for adverse outcomes in COVID-19, although patients with diabetes and ischaemic heart disease were at particular risk. Additional risk factors which significantly and independently associated with poorer outcomes in patients with diabetes were age, male gender and lower platelet count. Antiplatelet medication was associated with a lower risk of death/ICU admission and should be evaluated in randomised clinical trials amongst high risk patient groups.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe Section of Endocrinology and Investigative Medicine is funded by grants from the MRC, BBSRC, NIHR and is supported by the NIHR Biomedical Research Centre Funding Scheme. The views expressed are those of the authors and not necessarily those of the MRC, BBSRC, the NHS, the NIHR or the Department of Health and Social Care. CI is funded by an Imperial-BRC IPPRF Fellowship, JK is funded by an NIHR Doctoral Research Fellowship (DRF-2017-10-042), SM is funded by a Future Leaders Mentorship Award from the European Association for the Study of Diabetes, TT is funded by the MRC and NIHR, VS is funded by a Harry Keen Diabetes UK Fellowship.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Head of Research Governance and Integrity at Imperial College Healthcare NHS Trust (the healthcare organisation where the data used in the manuscript was collected) confirmed that approval from a Research Ethics Committee was not required. AS part of this submission, we have uploaded the letter confirming this as a Supplementary Material file.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData requests should be made to the corresponding author.